Osteopontin: A new placental biomarker for fetal growth restriction
A prospective case-control study published in the International Journal of Gynecology & Obstetrics has identified osteopontin as a promising biomarker for fetal growth restriction (FGR). Researchers measured osteopontin levels in maternal serum and placental tissue from 40 women with FGR and 40 matched controls. They found significantly reduced levels of osteopontin in both sample types from the FGR group compared to healthy pregnancies. The study demonstrated that placental osteopontin, normalized to total protein, offered the best predictive performance for identifying FGR, with a sensitivity of 77.5% and specificity of 70.0%. Furthermore, lower osteopontin levels were also predictive of composite adverse neonatal outcomes, suggesting its role extends beyond diagnosis to prognosis.
Why it might matter to you: This research highlights the ongoing search for reliable biomarkers to improve the diagnostic and prognostic accuracy for complex conditions like FGR. For professionals in laboratory medicine, it underscores the potential clinical utility of immunoassays, like the ELISA used here, in obstetric care. The findings point toward a future where specific protein assays could become integral to prenatal testing panels, aiding in early identification and risk stratification, which is central to quality assurance and improving patient outcomes through precise diagnostic algorithms.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
